Experience

• 

  Immacule Lifesciences

  • Nalagarh, Himachal Pradesh, India

  • Assistant Manager

    • Nov 2021 - Present
    • Nalagarh, Himachal Pradesh, India

    Immacule Lifesciences is the fastest growing One Stop Solution for Injectable, from Development to commercial manufacturing of injectable in liquid in aqueous/non aqueous as well as in Lyophilized dosage forms in vial and ampoules in non-oncology space with robust capabilities for terminal sterilization as well as aseptically filled injectable. With global footprint across countries, including the United States, Europe, Australia and other emerging markets, we are backward integrated in the pharmaceutical research and development alongside manufacturing complex injectable.Immacule, in its newly acquired land has plans to fuel in USD50 million to expand its drug product manufacturing capacity, in turn serving the industry’s pipeline across “various modalities”. Specifically, the expansion will bring on new freeze-drying capacity, Prefilled syringe & Cartridge capacity as well as mark its entry into Oncology injections. In all, 3 new lines are planned which will further consolidate Immacule’s position in fill finish CDMO category for the global market.by January 2024. On the current business front, Immacule will continue to focus on First to File 505 (b)(2), NCEs & complex generics niche products scale-up, exhibit batches & commercial manufacturing support services to its global clients.

• 

  Ind Swift

  • Dera Bassi, Punjab, India

  • Assistant Manager

    • Nov 2017 - Nov 2021
    • Dera Bassi, Punjab, India

    The Ace unit of Ind Swift Limited was created in the year 2005 with an aim to globalize the Ind Swift brand for finished dosage forms. The manufacturing site catering to the demand of the developed international markets was commissioned in 2006. A record was created when two major regulatory approvals, one from MHRA, UK and the other from TGA, Australia were received for this site within a record time of the site being commissioned. The approvals opened the gates for GBU to become a key supplier of products to the countries of EU, Australia, Canada, Singapore etc.The products from GBU are now available in more than 30 countries across the world spanning the countries of EU, Australia, Central & Latin America, Asia, CIS and Africa. The product selection for the various markets is based on the patent expiries in the developed countries and the high growth therapeutic segments like Cardiology, Diabetology, Osteoarthritis etc in the emerging markets.Branch offices in Singapore, Dubai and China underline GBU's direct market presence in key regions.With the increasing regulatory demands from across the globe, GBU is geared up to handle all kinds of queries from the Ministry of Health of different countries and has about 300 products registered globally with another about 500 in the pipeline. GBU has regular audits from the country and company representatives and is always honored for the GMP standards that are maintained.The focus of GBU for the prospective years is clear and the ground has already been laid. The markets where the attention will be centered for future growth are GCC, MENA, Brazil, Mexico, Africa, Russia and the CIS countries. GBU has already received the regulatory approvals from the MOH- UAE, GCC, Anvisa-Brazil and is now building the product portfolio for specific markets. The business models to be followed would include licensing and supply arrangements and marketing of our own brands in these countries by setting up representative office

• 

  SUN PHARMA

  • Mohali (Punjab)

  • Executive

    • Feb 2017 - Nov 2017
    • Mohali (Punjab)

    Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.

• 

  MACLEODS PHARMACEUTICALS LTD

  • Baddi

  • Executive

    • Oct 2012 - Feb 2017
    • Baddi

    Worked in validation section in aVertically Integrated Global Pharmaceutical Company Having a vision to provide quality healthcare to humanity and with special focus on essential and difficult to make medicines, Macleods Pharmaceuticals Ltd, was incorporated in 1986. Macleods has enjoyed rapid growth in the recent years, growing at an average growth rate of over 22% for the past 5 years. Macleods with its experience spanning more than two decades has emerged as a force to reckon with in global pharmaceutical market. With an asset of more than 10,000 professionally qualified employees across the globe, Macleods a multiple location organization, is based out of Mumbai, India. With expertise in range of formulations ranging from tablets to sterile dosage form and from inhalation to novel drug delivery system, Macleods is currently ranked 10th (on mat basis source IMS) in Indian Pharmaceutical Industry and is recognized as one of the fastest growing pharmaceutical company in India. Pioneering efforts of Macleods in providing medications for both chronic and acute therapy, with world- class state-of-the-art manufacturing facilities approved by various regulatory authorities of many countries and well equipped R&D, analytical and bioequivalence center audited by various regulatory authorities makes Macleods truly a global pharmaceutical company.

• 

  Cipla Ltd Baddi

  • Baddi

  • Chromatographer

    • Dec 2010 - Oct 2012
    • Baddi

    Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. Our portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally. Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.

• 

  Santo Formulations(A unit of Meridian Group)

  • solan (H.P)

  • Quality Analyst

    • May 2007 - Dec 2010
    • solan (H.P)

    My first company from where i started my pharmaceutical carrer in quality control department.